IQVIA (NYSE:IQV) Hits New 1-Year High – Here’s What Happened

IQVIA Holdings Inc. (NYSE:IQV)’s stock price reached a new 52-week high during mid-day trading on Monday . The company traded as high as $228.22 and last traded at $228.1770, with a volume of 679441 shares traded. The stock had previously closed at $224.90.

Analyst Ratings Changes

IQV has been the subject of several research analyst reports. Jefferies Financial Group raised IQVIA from a “hold” rating to a “buy” rating and increased their price objective for the company from $195.00 to $225.00 in a report on Tuesday, September 9th. Stifel Nicolaus upped their price target on shares of IQVIA from $234.00 to $254.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. TD Cowen downgraded shares of IQVIA from a “buy” rating to a “hold” rating and raised their price objective for the stock from $206.00 to $215.00 in a research report on Monday, November 3rd. Truist Financial restated a “buy” rating and issued a $265.00 price target (up previously from $235.00) on shares of IQVIA in a research report on Wednesday, October 29th. Finally, BMO Capital Markets began coverage on IQVIA in a research report on Thursday, November 13th. They set an “outperform” rating and a $260.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $240.61.

IQVIA Stock Down 0.2%

The firm’s 50-day simple moving average is $208.43 and its 200 day simple moving average is $182.71. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70. The company has a market capitalization of $39.43 billion, a PE ratio of 22.02, a price-to-earnings-growth ratio of 2.60 and a beta of 1.34.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The company had revenue of $4.10 billion during the quarter, compared to the consensus estimate of $4.07 billion. During the same period last year, the firm earned $2.84 EPS. The company’s revenue for the quarter was up 5.2% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the transaction, the insider owned 27,108 shares of the company’s stock, valued at $5,955,627.60. This trade represents a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.60% of the stock is currently owned by insiders.

Institutional Trading of IQVIA

Institutional investors have recently modified their holdings of the company. Verdence Capital Advisors LLC bought a new stake in IQVIA during the second quarter valued at approximately $3,612,000. Patton Fund Management Inc. bought a new stake in shares of IQVIA during the 2nd quarter valued at $231,000. Heritage Investors Management Corp increased its stake in shares of IQVIA by 10.5% in the 2nd quarter. Heritage Investors Management Corp now owns 104,704 shares of the medical research company’s stock worth $16,500,000 after purchasing an additional 9,909 shares in the last quarter. Shell Asset Management Co. raised its holdings in IQVIA by 78.7% in the 2nd quarter. Shell Asset Management Co. now owns 9,256 shares of the medical research company’s stock worth $1,459,000 after purchasing an additional 4,077 shares during the period. Finally, Nordea Investment Management AB lifted its position in IQVIA by 41.7% during the second quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock valued at $326,274,000 after purchasing an additional 606,391 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.